WO1994012171A1 - Compositions injectables a base de derives des taxanes - Google Patents

Compositions injectables a base de derives des taxanes Download PDF

Info

Publication number
WO1994012171A1
WO1994012171A1 PCT/FR1993/001166 FR9301166W WO9412171A1 WO 1994012171 A1 WO1994012171 A1 WO 1994012171A1 FR 9301166 W FR9301166 W FR 9301166W WO 9412171 A1 WO9412171 A1 WO 9412171A1
Authority
WO
WIPO (PCT)
Prior art keywords
compositions according
additive
surfactant
solution
chosen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1993/001166
Other languages
English (en)
French (fr)
Inventor
Jean-Marc Bobee
Patrick De Lanty
Gilles Guerin
Michel Veillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994012171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1019950702223A priority Critical patent/KR100330316B1/ko
Priority to CA002150576A priority patent/CA2150576C/fr
Priority to SK725-95A priority patent/SK281558B6/sk
Priority to AU55669/94A priority patent/AU691476B2/en
Priority to JP50090394A priority patent/JP3689791B2/ja
Priority to PL93309197A priority patent/PL174334B1/pl
Priority to DE69328192T priority patent/DE69328192T4/de
Priority to AT94900881T priority patent/ATE190838T1/de
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to DK94900881T priority patent/DK0671912T3/da
Priority to RU95113494A priority patent/RU2144356C1/ru
Priority to HU9501596A priority patent/HU222833B1/hu
Priority to DE69328192A priority patent/DE69328192D1/de
Priority to EP94900881A priority patent/EP0671912B1/fr
Publication of WO1994012171A1 publication Critical patent/WO1994012171A1/fr
Priority to NO19952151A priority patent/NO314436B1/no
Priority to FI952680A priority patent/FI113619B/fi
Anticipated expiration legal-status Critical
Priority to GR990401833T priority patent/GR3032828T3/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a new pharmaceutical form based on a therapeutic agent having an antitumor and antileukemic activity. It relates more particularly to a new injectable form containing taxoids such as taxol, taxotere or derivatives of the following general formula:
  • R represents a hydrogen atom or an acetyl radical
  • Ri represents a tert-butoxycarbonylamino or benzoyloxyamino radical.
  • R represents an acetyl group and R-
  • the first of these two compounds is better known under the name of taxol, the second is known under the name of Taxotere.
  • mother solution containing approximately 6 mg / ml of taxol in a solvent mixture composed of:
  • this solution When injected, this solution is mixed with an infusion fluid containing sodium chloride or dextrose. To obtain a stable mixture, from both a physical and a chemical point of view, the authors of this article say that the concentration of active ingredient in the infusion solution must be limited to concentrations of approximately 0.03 0.6 mg / ml (see previous publication page 1251 column 1, third paragraph).
  • a mother solution was prepared containing the active principle in a mixture of solvents composed of ethanol which is the best biocompatible solvent for the active principles of the class of taxanes and a surfactant chosen from the polysorbates sold in particular under the names Tween and Montanox, or the ether-ether of ethylene oxide and fatty acid glycerides (hydrogenated or non-hydrogenated castor oil) sold for example under the name Cremophor or Emulphor.
  • the stock solution was prepared by dissolving the active ingredient in ethanol and then gradually adding the surfactant. It was thus possible to prepare solutions containing 10 to 100 mg / ml of active principle in a mixture containing approximately 50% of surfactant. The ethanol contained in this solution was then removed at least partially by evaporation under vacuum or by any other suitable means.
  • the active principle was directly dissolved in the surfactant.
  • a surfactant solution containing in particular 1 to 2% of ethanol was prepared and the active principle was continuously added to this solution by stirring using for example a grinder helical or a grinding turbine.
  • the presence of a small amount of ethanol provides several advantages, the medium has a lower viscosity, the wetting of the powder is improved as well as the final filtration of the solution.
  • the stock solution with a low ethanol content, preferably contains less than 5% of ethanol, it even more preferably contains less than 2% ethanol.
  • This solution is stable and can thus contain up to 200 mg / ml and preferably up to 80 mg / ml of active principle in the surfactant.
  • the stock solution of taxol had according to this invention a concentration of between 6 and 20 mg / ml of active principle in the surfactant.
  • the parent solution of Taxotere preferably had a concentration of between 20 and 80 mg / ml of active principle in the surfactant.
  • Another solution for dissolving the mother solution in the infusion solution consists in heating the whole to around 40 ° C. But in this case, the compound of formula (I) is partially degraded
  • the present invention therefore consists in producing an intermediate solution between the solution of derivatives of the taxane class in the surfactant and an aqueous solution containing an additive subsequently promoting the dissolution of said intermediate solution in the infusion solution.
  • additives are chosen from all of the additives which are capable of breaking or avoiding the formation of the gelled phase which is formed between the emulsifier containing the derivative of the taxane class and water.
  • additives making it possible to break or avoid the formation of this gelled phase
  • derivatives having a molecular weight equal to or less than about 200.
  • these compounds those more preferred are those which carry at least one hydroxyl function or an amino function such as amino acids.
  • Mineral salts such as sodium chloride can also be used.
  • the amount of additive used varies depending on the nature of the additive, it is preferably greater than 6% by weight relative to the mass of surfactant and even more preferably greater than 15% by weight for the polyols such than glycerol, glucose or sorbitol.
  • solutions of the taxoids in the surfactant with the aqueous solution of the dilution additive are preferably presented in ampoules, vials or a double-compartment device allowing the extemporaneous mixing of the two solutions at the time of injection into the infusion bag.
  • Taxotere or taxol infusions are then injected into humans at a predetermined rate depending on the amount of active ingredient that one wants to inject. We do not observe with these solutions the phenomena of anaphylactic shocks that we observed with the solutions of the prior art. Thus these last infusions have made it possible to reduce, compared to the prior art, the amounts of surfactant injected into humans by approximately 80%.
  • the solution obtained is stable, it contains 40 mg / ml of Taxotere.
  • Example 1 is repeated, replacing the glycerol solution with an aqueous glucose solution containing 35% by weight of glucose. After manual stirring, the solution is fluid.
  • EXAMPLES 3 to 4 are repeated, replacing the glycerol solution with an aqueous glucose solution containing 35% by weight of glucose. After manual stirring, the solution is fluid.
  • Example 1 is reproduced, replacing the Polysorbate with different surfactants the results are shown in the following table:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)
PCT/FR1993/001166 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes Ceased WO1994012171A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP94900881A EP0671912B1 (fr) 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes
CA002150576A CA2150576C (fr) 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes
SK725-95A SK281558B6 (sk) 1992-12-02 1993-11-26 Injikovateľná kompozícia na prípravu infúzneho roztoku obsahujúca deriváty skupiny taxánov
AU55669/94A AU691476B2 (en) 1992-12-02 1993-11-26 Injectable taxane derivative based compositions
JP50090394A JP3689791B2 (ja) 1992-12-02 1993-11-26 タキソイドに基づく新規な組成物
PL93309197A PL174334B1 (pl) 1992-12-02 1993-11-26 Sposób wytwarzania kompozycji do iniekcji zawierającej pochodne z grupy taksanów przeznaczonej do przygotowania roztworu do perfuzji
DE69328192T DE69328192T4 (de) 1992-12-02 1993-11-26 Injizierbare Arzneizubereitungen enthaltend Taxanderivate
AT94900881T ATE190838T1 (de) 1992-12-02 1993-11-26 Injizierbare arzneizubereitungen enthaltend taxanderivate
DK94900881T DK0671912T3 (da) 1992-12-02 1993-11-26 Injicerbare præparater baseret på taxanderivater
KR1019950702223A KR100330316B1 (ko) 1992-12-02 1993-11-26 탁산유도체를기재로한주사용조성물
DE69328192A DE69328192D1 (de) 1992-12-02 1993-11-26 Injizierbare Arzneizubereitungen enthaltend Taxanderivate
HU9501596A HU222833B1 (hu) 1992-12-02 1993-11-26 Taxánszármazékot tartalmazó injektálható gyógyszerkészítmények
RU95113494A RU2144356C1 (ru) 1992-12-02 1993-11-26 Композиция для инъекций на основе таксоидов
NO19952151A NO314436B1 (no) 1992-12-02 1995-05-31 Injiserbare, taxanderivat-baserte preparater
FI952680A FI113619B (fi) 1992-12-02 1995-06-01 Menetelmä injektoitavien taksaanijohdannaisiin pohjautuvien koostumusten valmistamiseksi
GR990401833T GR3032828T3 (en) 1992-12-02 2000-03-23 Injectable taxane derivative based compositions.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.
FR92/14501 1992-12-02

Publications (1)

Publication Number Publication Date
WO1994012171A1 true WO1994012171A1 (fr) 1994-06-09

Family

ID=9436137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1993/001166 Ceased WO1994012171A1 (fr) 1992-12-02 1993-11-26 Compositions injectables a base de derives des taxanes

Country Status (28)

Country Link
US (1) US5438072A (https=)
EP (1) EP0671912B1 (https=)
JP (1) JP3689791B2 (https=)
KR (1) KR100330316B1 (https=)
CN (2) CN1291713C (https=)
AT (1) ATE190838T1 (https=)
AU (1) AU691476B2 (https=)
CA (1) CA2150576C (https=)
CZ (1) CZ284080B6 (https=)
DE (2) DE69328192D1 (https=)
DK (1) DK0671912T3 (https=)
ES (1) ES2145115T4 (https=)
FI (1) FI113619B (https=)
FR (1) FR2698543B1 (https=)
GE (1) GEP19991856B (https=)
GR (1) GR3032828T3 (https=)
HU (1) HU222833B1 (https=)
MX (1) MX9306986A (https=)
NO (1) NO314436B1 (https=)
NZ (1) NZ258150A (https=)
PL (1) PL174334B1 (https=)
PT (1) PT671912E (https=)
RU (1) RU2144356C1 (https=)
SK (1) SK281558B6 (https=)
TW (1) TW271395B (https=)
WO (1) WO1994012171A1 (https=)
YU (1) YU49092B (https=)
ZA (1) ZA938936B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041850A1 (en) * 1996-05-02 1997-11-13 Yeong Wook Song Paclitaxel for the treatment of rheumatic diseases
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
WO1998057630A1 (fr) * 1997-06-13 1998-12-23 Laboratoires Thissen (L.T.B.) Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition
EP0876145A4 (en) * 1995-12-21 1999-04-21 Genelabs Tech Inc TAX COMPOSITION AND PROCEDURE
EP0920311A4 (en) * 1996-06-28 2001-10-04 Univ Texas PARENTERAL PACLITAXEL IN A STABLE NON-TOXIC FORMULATION
DE19655141B4 (de) 1996-11-08 2005-04-07 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
WO1998049321A2 (en) * 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
CA2367661A1 (en) * 2000-02-02 2001-08-09 Robert A. Holton Taxane formulations having improved solubility
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
CN1555253A (zh) * 2001-09-13 2004-12-15 ������ѧ�����о�Ժ 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CN101134119A (zh) * 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2536242A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
JP4820758B2 (ja) 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
JP2008543789A (ja) 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー ドセタキセルの液体薬学的処方物
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
RU2447095C2 (ru) 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
US10094836B2 (en) 2007-01-08 2018-10-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SLCO1B3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
AR063111A1 (es) * 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
JP5667886B2 (ja) 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
AU2008352597B2 (en) 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
ES2862340T3 (es) 2009-10-29 2021-10-07 Sanofi Mature Ip Nuevo uso antitumoral de cabazitaxel
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
PH12012501662A1 (en) 2010-02-18 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Triazolo [4,5 - b] pyridin derivatives
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
KR20140024833A (ko) 2010-11-17 2014-03-03 니폰 가야꾸 가부시끼가이샤 신규한 시티딘계 대사길항제의 고분자 유도체
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012135781A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
PL2710018T3 (pl) 2011-05-19 2022-04-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Związki makrocykliczne jako inhibitory kinaz białkowych
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
RS58146B1 (sr) 2011-09-08 2019-02-28 Univ New York Onkolitički herpes simpleks virus i njegova terapeutska upotreba
CN103874722B (zh) 2011-09-11 2016-06-29 日本化药株式会社 嵌段共聚物的制造方法
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US10238723B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CN111465389B (zh) 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118316A2 (en) * 1983-03-07 1984-09-12 Lipid Specialties, Inc. Synthetic phospholipid compounds, their preparation and use
EP0253738A1 (fr) * 1986-07-17 1988-01-20 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0522937A1 (fr) * 1991-07-08 1993-01-13 Aventis Pharma S.A. Compositions à base de dérivés de la classe des taxanes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
JP2919867B2 (ja) * 1989-09-27 1999-07-19 千寿製薬株式会社 抗腫瘍剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118316A2 (en) * 1983-03-07 1984-09-12 Lipid Specialties, Inc. Synthetic phospholipid compounds, their preparation and use
EP0253738A1 (fr) * 1986-07-17 1988-01-20 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0522937A1 (fr) * 1991-07-08 1993-01-13 Aventis Pharma S.A. Compositions à base de dérivés de la classe des taxanes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.D.TARR ET AL.: "A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs", J.PARENTER.SCI.TECHNOL., vol. 41, no. 1, 1987, pages 31 - 33 *
CHEMICAL ABSTRACTS, vol. 106, no. 22, 1 June 1987, Columbus, Ohio, US; abstract no. 182581c *
E.K.ROWINSKY ET AL.: "Taxol:a novel investigational antimicrotubule agent", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 82, no. 15, 1 August 1990 (1990-08-01), pages 1247 - 1259 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0876145A4 (en) * 1995-12-21 1999-04-21 Genelabs Tech Inc TAX COMPOSITION AND PROCEDURE
WO1997041850A1 (en) * 1996-05-02 1997-11-13 Yeong Wook Song Paclitaxel for the treatment of rheumatic diseases
EP0920311A4 (en) * 1996-06-28 2001-10-04 Univ Texas PARENTERAL PACLITAXEL IN A STABLE NON-TOXIC FORMULATION
DE19655141B4 (de) 1996-11-08 2005-04-07 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten
WO1998053810A1 (en) * 1997-05-30 1998-12-03 Man Woo Han Pharmaceutical injection solution containing taxol
WO1998057630A1 (fr) * 1997-06-13 1998-12-23 Laboratoires Thissen (L.T.B.) Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.

Also Published As

Publication number Publication date
ES2145115T3 (es) 2000-07-01
NO314436B1 (no) 2003-03-24
YU74593A (sh) 1996-08-13
NZ258150A (en) 1996-11-26
CA2150576A1 (fr) 1994-06-09
FI952680L (fi) 1995-06-01
ES2145115T4 (es) 2010-06-17
CN1291713C (zh) 2006-12-27
JP3689791B2 (ja) 2005-08-31
ZA938936B (en) 1994-08-03
SK281558B6 (sk) 2001-05-10
CN1636560A (zh) 2005-07-13
EP0671912B1 (fr) 2000-03-22
NO952151L (no) 1995-05-31
PL309197A1 (en) 1995-09-18
KR100330316B1 (ko) 2002-11-04
FI952680A0 (fi) 1995-06-01
FI113619B (fi) 2004-05-31
HUT72650A (en) 1996-05-28
DE69328192T4 (de) 2007-07-19
JPH08503689A (ja) 1996-04-23
HK1075197A1 (en) 2005-12-09
EP0671912A1 (fr) 1995-09-20
CN1090170A (zh) 1994-08-03
PT671912E (pt) 2000-06-30
FR2698543B1 (fr) 1994-12-30
YU49092B (sh) 2003-12-31
AU691476B2 (en) 1998-05-21
RU2144356C1 (ru) 2000-01-20
GR3032828T3 (en) 2000-06-30
DE69328192D1 (de) 2000-04-27
CZ284080B6 (cs) 1998-08-12
GEP19991856B (en) 1999-12-06
DE69328192T2 (de) 2000-09-28
PL174334B1 (pl) 1998-07-31
TW271395B (https=) 1996-03-01
KR950703946A (ko) 1995-11-17
MX9306986A (es) 1995-01-31
HU9501596D0 (en) 1995-08-28
CZ142195A3 (en) 1995-10-18
FR2698543A1 (fr) 1994-06-03
HU222833B1 (hu) 2003-11-28
US5438072A (en) 1995-08-01
DK0671912T3 (da) 2000-07-03
NO952151D0 (no) 1995-05-31
AU5566994A (en) 1994-06-22
CA2150576C (fr) 2005-06-21
SK72595A3 (en) 1995-11-08
ATE190838T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
EP0671912B1 (fr) Compositions injectables a base de derives des taxanes
EP0593601B1 (fr) Nouvelles compositions a base de derives de la classe des taxanes
JP2618596B2 (ja) タキサン類の誘導体を基とする新規組成物
US5714512A (en) Compositions containing taxane derivatives
US5698582A (en) Compositions containing taxane derivatives
WO1995028923A1 (fr) Compositions pharmaceutiques a base de derives de la classe des taxanes
EP2197492A1 (fr) Nouvelles compositions a base de taxoides
CA2188599C (fr) Compositions pharmaceutiques a base de derives de la classe des taxanes
HK1006207B (en) Novel compositions based on taxane class derivatives
HK1075197B (en) New composition containing taxane derivatives as major component

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CZ FI HU JP KR NO NZ PL RU SK

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994900881

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2150576

Country of ref document: CA

Ref document number: 258150

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 72595

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV1995-1421

Country of ref document: CZ

Ref document number: 952680

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1994900881

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-1421

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1995-1421

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994900881

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 952680

Country of ref document: FI